Short-acting triazolobenzodiazepine — positive allosteric modulator at GABA-A BZD site (α1-preferring). Used for short-term insomnia and procedural sedation. Extensively metabolized by CYP3A4 — sensitive to CYP3A inhibitors (azoles, ritonavir, clarithromycin) which can extend the t½ markedly. Rapid onset, short duration.
Half-Life & Elimination Curve (PO: 2.6h)
Plasma (PO)t½ Decay (2.6h)Effect Site (ke0)
0×t½0h100%(0.983 µg/L)
1×t½2.6h50%(0.492 µg/L)
2×t½5.2h25%(0.246 µg/L)
3×t½7.8h12.5%(0.123 µg/L)
4×t½10.4h6.3%(0.0615 µg/L)
5×t½13h3.1%(0.0307 µg/L)
Elimination t½2.6h (PO)
Rate Constant (ke)0.267 h⁻¹
Time to Peak (Tmax)1.4h
Est. Peak (Cmax)0.983 µg/L
Clearance (CL)20.5 L/h
97% Washout (5×t½)13h
Dosing Guidelines
Oral (PO): Typical 0.25 mg (Range: 0.125–0.5 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 44% · Volume of Distribution (Vd): 77 L · Absorption (ka): 1.5 h⁻¹ (t½ka ≈ 28m) [PMID 3567010]